Pages that link to "Q39437895"
Jump to navigation
Jump to search
The following pages link to Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections (Q39437895):
Displaying 50 items.
- Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults (Q22242958) (← links)
- Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children (Q24203905) (← links)
- Neuraminidase inhibitors for preventing and treating influenza in healthy adults (Q24240097) (← links)
- Neuraminidase inhibitors for preventing and treating influenza in healthy adults (Q24244898) (← links)
- Mutations in human parainfluenza virus type 3 hemagglutinin-neuraminidase causing increased receptor binding activity and resistance to the transition state sialic acid analog 4-GU-DANA (Zanamivir). (Q24540532) (← links)
- Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells (Q24559989) (← links)
- Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis (Q24644585) (← links)
- Inhaled anti-infective chemotherapy for respiratory tract infections: successes, challenges and the road ahead (Q26822988) (← links)
- Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention (Q28201389) (← links)
- Binding of a natural anthocyanin inhibitor to influenza neuraminidase by mass spectrometry (Q28292279) (← links)
- Zanamivir: from drug design to the clinic (Q28344586) (← links)
- The anti-influenza virus agent 4-GU-DANA (zanamivir) inhibits cell fusion mediated by human parainfluenza virus and influenza virus HA. (Q28344907) (← links)
- Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities (Q28349496) (← links)
- In vivo influenza virus-inhibitory effects of the cyclopentane neuraminidase inhibitor RJW-270201 (Q28349519) (← links)
- The Intranasal Application of Zanamivir and Carrageenan Is Synergistically Active against Influenza A Virus in the Murine Model (Q28547982) (← links)
- Estimating the United States demand for influenza antivirals and the effect on severe influenza disease during a potential pandemic (Q30204152) (← links)
- Cost effectiveness of oseltamivir treatment for patients with influenza-like illness who are at increased risk for serious complications of influenza: illustration for the Netherlands (Q30229855) (← links)
- The threat and prospects for control of an influenza pandemic (Q30233313) (← links)
- Influenza virus neuraminidase inhibitors (Q30305461) (← links)
- Recent progress in anti-influenza chemotherapy. (Q30326042) (← links)
- What is current opinion of antiviral therapy for the flu in 2001? (Q30327921) (← links)
- New millennium antivirals against pandemic and epidemic influenza: the neuraminidase inhibitors. (Q30332341) (← links)
- The treatment of influenza with antiviral drugs (Q30332377) (← links)
- Treatment of epidemic and pandemic influenza with neuraminidase and M2 proton channel inhibitors (Q30332727) (← links)
- Novel strategies for prevention and treatment of influenza. (Q30350342) (← links)
- Antivirals for influenza in healthy adults: systematic review. (Q30352729) (← links)
- Pandemics, avian influenza A (H5N1), and a strategy for pharmacists. (Q30353151) (← links)
- Influenza testing, diagnosis, and treatment in the emergency department in 2009-2010 and 2010-2011 (Q30353587) (← links)
- Effectiveness of neuraminidase inhibitors in preventing hospitalization during the H1N1 influenza pandemic in British Columbia, Canada. (Q30356962) (← links)
- Scientific lessons from the first influenza pandemic of the 20th century. (Q30357693) (← links)
- Bird flu: lessons from SARS. (Q30362366) (← links)
- An overview of the characteristics of the novel avian influenza A H7N9 virus in humans. (Q30372931) (← links)
- Influenza vaccines: from surveillance through production to protection. (Q30385118) (← links)
- Update on antivirals and vaccines for seasonal and potential pandemic use. (Q30389265) (← links)
- Drugs in development for influenza (Q30391218) (← links)
- Influenza and HIV: lessons from the 2009 H1N1 influenza pandemic (Q30404293) (← links)
- Influenza virus resistance to neuraminidase inhibitors: implications for treatment (Q30411822) (← links)
- Prophylactic and symptomatic treatment of influenza. Current and developing options (Q31992333) (← links)
- Antiviral agents for influenza: a comparison of cost-effectiveness data (Q33226840) (← links)
- How to treat influenza and colds (Q33727502) (← links)
- Zanamivir: a review of clinical safety (Q33748023) (← links)
- Zanamivir: a review of its use in influenza (Q33768776) (← links)
- Effectiveness and role of zanamivir in the treatment of influenza infection (Q33780690) (← links)
- Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies (Q33978456) (← links)
- Prescription of anti-influenza drugs for healthy adults: a systematic review and meta-analysis. (Q34018854) (← links)
- In vitro and in vivo assay systems for study of influenza virus inhibitors (Q34083704) (← links)
- Cost-utility of rapid polymerase chain reaction-based influenza testing for high-risk emergency department patients. (Q34171619) (← links)
- Influenza. Cost of illness and considerations in the economic evaluation of new and emerging therapies (Q34219687) (← links)
- Zanamivir and oseltamivir: two new options for the treatment and prevention of influenza (Q34229084) (← links)
- The use of antiviral drugs for influenza: Guidance for practitioners 2012/2013 (Q34389114) (← links)